ValuEngine upgraded shares of Zeltia (OTCMKTS:PHMMF) from a sell rating to a hold rating in a research report sent to investors on Wednesday, May 2nd.
Separately, Zacks Investment Research downgraded Zeltia from a hold rating to a sell rating in a research report on Thursday, January 25th.
OTCMKTS:PHMMF opened at $1.92 on Wednesday. Zeltia has a 12 month low of $1.84 and a 12 month high of $4.80.
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. The company operates through two segments, Biopharmaceuticals and Consumer Chemicals. It develops and commercializes YONDELIS, an antitumor agent for the treatment of advanced soft tissue sarcomas and for relapsed ovarian cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zeltia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltia and related companies with MarketBeat.com's FREE daily email newsletter.